In mice with IBD induced by LPS, oral administration of PLGA-RMP can also regulate macrophage polarization, inhibit specific inflammatory cytokines (including TNF-α, IL-6, IL-1β, PGE2), inhibit the activation of CD3+CD8+ T cells, increase the number of activated Treg in the intestine, and reduce the DAI score and intestinal inflammatory damage. This evidence concerns the gene IL6 and inflammatory bowel disease.